Paul Testa, executive vice president for operations and supply chain at Tokyo-based Kyowa Kirin, on the dramatic importance of continuity, reliability of supply, business process and automation.
Peter Pitts, president of the Center for Medicine in the Public Interest, on how government regulation seems like a slow but in actuality moves more quickly than understood.
Joseph Allen, executive director of the Bayh-Dole Coalition, explains how molnupiravir, from Ridgeback Biotherapeutics, and partner Merck & Co. Inc., may have never had a chance to move out of the university onto pharmacy shelves without the government’s support.
The approval of antibody-drug conjugate Tivdak (tisotumab vedotin) for treating cervical cancer and the future of Genmab A/S are the subjects with the company's president and CEO, Jan van de Winkel.
An in-depth conversation with Lucio Rovati, CEO and chief scientific officer of Italy’s Rottapharm Biotech as they tackle the new world of DNA vaccines.